Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a serious public …

Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to
public health since its emergence in late 2019. From a safety point of view, drug repurposing …

Many patients affected by COVID-19 suffer from debilitating persistent symptoms whose risk
factors remained poorly understood. This prospective study examined the association of …

Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …

Initially, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus
responsible for coronavirus disease-2019 (COVID-19), was predominantly considered to …

Background Patients with severe mental illness (SMI)(ie, schizophrenia, bipolar disorder, or
major depressive disorder) have been reported to have excess mortality rates from infection …

Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …

Background Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is a
poorly understood condition with symptoms across a range of biological domains that often …

Fluvoxamine (FXM) is a well-known selective serotonin reuptake inhibitor (SSRI) for treating
depression and has recently been repurposed for efficacious treatment of coronavirus …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in
hundreds of millions of coronavirus cases, as well as millions of deaths worldwide …